Compare Incyte Corporation (INCY) vs Prologis Inc (PLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Prologis Inc — how do they compare? Incyte Corporation trades at $120.8 (market cap $24.54B), while Prologis Inc trades at $140.01 (market cap $132.57B). The key difference: Prologis Inc is far larger — about 5.4× Incyte Corporation's market cap, and Prologis Inc pays a 3.07% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | PLD | |
|---|---|---|
Market Cap | $24.54B | $132.57B |
Sector | Health | Real Estate |
52-Week High | $129.93 | $149.96 |
52-Week Low | $81.61 | $104.81 |
Enterprise Value | $20.04B | $167.31B |
Dividend Yield | — | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Prologis (PLD) trades at $139.75, up 0.74% today, with strong recent earnings beats but a bearish technical signal. The company announced a major $18.8 billion acquisition of SEGRO, expanding its European footprint, while financials show robust profitability with a 45.79% net income margin. Cash flow trends are mixed, with 2025 showing a net outflow but a projected recovery in 2026.
The outlook is positive due to strategic growth via acquisition and consistent earnings outperformance, though risks include integration challenges from the SEGRO deal and a high P/E ratio of 31.07. Analyst consensus is bullish with a $159.22 price target, suggesting significant upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →
